Veritas In Silico Inc. [130A.T]
TOKYO, May 11 (Pulse News Wire) – Veritas In Silico Inc. (130A.T) reported a lower net profit of ¥256 million for the quarter ending March 2026, despite recognizing several key milestones.
Operating expenses stood at ¥139 million, while revenue was ¥17 million. The company noted a ¥135 million impairment loss but maintained its annual earnings forecast. In pipeline developments, Veritas initiated animal trials for its first drug candidate and filed patent applications for potential drug substances.
Notably, the company held a joint press conference with Tokyo Jikei University Medical School upon the publication of a patent for a novel nucleic acid-based treatment for ALS. Regarding Perfusio, the company's proprietary drug delivery system, Veritas began consultations with PMDA for strategic discussions aimed at launching sales in 2027. The firm also continued negotiations with eight domestic and international partners to secure new contracts and advance its research initiatives.
🟡 Confidence: Standard AI-translated content.